Craig-Hallum analyst Alexander Nowak maintained a Buy rating on CVRx (CVRX – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at $28.03.
Nowak covers the Healthcare sector, focusing on stocks such as Guardant Health, CVRx, and QuidelOrtho. According to TipRanks, Nowak has an average return of 1.4% and a 42.19% success rate on recommended stocks.
Currently, the analyst consensus on CVRx is a Strong Buy with an average price target of $28.80, which is a 2.75% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $30.00 price target.
See today’s best-performing stocks on TipRanks >>
CVRX market cap is currently $583.5M and has a P/E ratio of -13.63.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVRx (CVRX) Company Description:
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases.
Read More on CVRX:
